Arrowhead Pharma (ARWR) PT Raised to $62 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $61.69 +3.63%
Rating Summary:
18 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
18 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Piper Sandler analyst Edward A. Tenthoff raised the price target on Arrowhead Pharma (NASDAQ: ARWR) to $62.00 (from $59.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Fortune Brands (FBIN) PT Lowered to $58 at DA Davidson
- Abbvie (ABBV) PT Raised to $315 at Freedom Broker
- Covista (CVSA) PT Raised to $146 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
